Retinal vein occlusion (RVO) is a major cause of blindness, and affected approximately 1.6 million patients in 2018 in the United States. Patients are segmented by the anatomic location of the occlusion, and therefore are classified as having branch, central, or hemi-retinal vein occlusion (BRVO, CRVO, HRVO, respectively). Because retinal vein occlusions compromise venous return from the retinal circulation, they may trigger retinal ischemia, macular edema and/or neovascularization. Intravitreally administered biologics targeting vascular endothelial growth factor (anti-VEGF agents; Roche/Genentech’s Avastin, Roche/Genentech’s Lucentis, Regeneron’s Eylea) and corticosteroids (Allergan’s Ozurdex) are used to treat macular edema following RVO. Although the pipeline for emerging RVO therapies is sparse, commercial opportunity exists for therapies with a longer dosing duration, greater efficacy, efficacy in treatment-resistant patients, and that are administered less invasively.


  • What diagnostic tests are used to characterize RVO patients, and how are different patient subtypes treated?
  • What are the key areas of unmet need and opportunity in the RVO market?
  • What are the key drivers and limiters in the RVO market?
  • What influence does each major player hold over the RVO market?
  • How is the RVO market expected to change over the next ten years?


United States


3 KOL interviews in April 2019


Regeneron, Roche/Genentech, Allergan, Novartis, Aerie Pharmaceuticals, Cerevast Medical, Taiwan Liposome Company, Kodiak Sciences

KEY DRUGS COVERED Avastin, Eylea, Lucentis, Ozurdex, brolucizumab, AR-1105, TLC399, KSI-301


Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.

Table of contents

  • Retinal Vein Occlusion - Executive Insights - Executive Insights (US)
    • Executive Insights - 2019 - Retinal Vein Occlusion

Author(s): Natalie Taylor, PhD

Natalie Taylor, Ph.D. is a Principal Business Insights Analyst with the central nervous system/ophthalmology disorders team at Decision Resources Group. She has over ten years of experience authoring primary and market research reports for pharmaceutical industry clients across multiple psychiatry, pain, neurology, and ophthalmology therapy areas.

Prior to joining DRG, Dr. Taylor worked at QuintilesIMS as manager of the central nervous system portfolio of Disease Insights market forecasting offerings. She completed her Ph.D. in Physiology at Dartmouth College in Hanover, New Hampshire, where she studied the role of serotonergic neurons in the medullary raphe on modulating respiratory responses in mammals. She holds a B.S. in Biology from Dickinson College in Carlisle, Pennsylvania.